74 related articles for article (PubMed ID: 12677235)
1. Novel Protease Inhibitors.
Norman P
Drug News Perspect; 2002 Jul; 15(6):372-382. PubMed ID: 12677235
[TBL] [Abstract][Full Text] [Related]
2. The Role of Bioinformatics in Identifying and Defining Potential Drug Targets.
Norman P
Drug News Perspect; 2002 May; 15(4):253-256. PubMed ID: 12677210
[TBL] [Abstract][Full Text] [Related]
3. Case Histories in Drug Discovery and Design 2001.
Drug News Perspect; 2002 Jan; 15(1):60-64. PubMed ID: 12677245
[TBL] [Abstract][Full Text] [Related]
4. Novel Perspectives in Medicinal Chemistry.
Norman P
Drug News Perspect; 2002 Jun; 15(5):313-320. PubMed ID: 12677227
[TBL] [Abstract][Full Text] [Related]
5. Protease Inhibition: Design, Technology & Opportunities--First RSC/SCI Symposium on Protease Inhibition.18-19 May 1998, London, UK.
Buckle DR
IDrugs; 1998 Jun; 1(2):185-8. PubMed ID: 18465527
[TBL] [Abstract][Full Text] [Related]
6. Research Strategies for Orphan G-Protein-Coupled Receptors.
Morris I; Williams R
Drug News Perspect; 2002 May; 15(4):249-252. PubMed ID: 12677209
[TBL] [Abstract][Full Text] [Related]
7. Proteomics: New Developments in Target Discovery.
Nagy JM; Brown KA
Drug News Perspect; 2002 Nov; 15(9):601-603. PubMed ID: 12677201
[TBL] [Abstract][Full Text] [Related]
8. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic Strategies in the Challenge of Cancer Treatment.
Norman P
Drug News Perspect; 2002 Dec; 15(10):675-680. PubMed ID: 12677253
[TBL] [Abstract][Full Text] [Related]
10. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease.
Khayat R; Batra R; Qian C; Halmos T; Bailey M; Tong L
Biochemistry; 2003 Feb; 42(4):885-91. PubMed ID: 12549906
[TBL] [Abstract][Full Text] [Related]
11. Successes and pitfalls of medical chemistry programs.
Norman P
Drug News Perspect; 2001 Nov; 14(9):551-67. PubMed ID: 12806443
[TBL] [Abstract][Full Text] [Related]
12. Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.
Shiraishi T; Kadono S; Haramura M; Kodama H; Ono Y; Iikura H; Esaki T; Koga T; Hattori K; Watanabe Y; Sakamoto A; Yoshihashi K; Kitazawa T; Esaki K; Ohta M; Sato H; Kozono T
Bioorg Med Chem Lett; 2008 Aug; 18(16):4533-7. PubMed ID: 18674905
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic Enzymes as Therapeutic Targets - Keystone Symposium. Targeting ICE and ACE. 3-8 February 2002, Keystone, CA, USA.
Loukas A
IDrugs; 2002 Mar; 5(3):220-1. PubMed ID: 15562330
[TBL] [Abstract][Full Text] [Related]
14. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
Specker E; Böttcher J; Brass S; Heine A; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
ChemMedChem; 2006 Jan; 1(1):106-17. PubMed ID: 16892342
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of chloromethyl sulfoxides as a new class of selective irreversible cysteine protease inhibitors.
Brouwer AJ; Bunschoten A; Liskamp RM
Bioorg Med Chem; 2007 Nov; 15(22):6985-93. PubMed ID: 17869119
[TBL] [Abstract][Full Text] [Related]
16. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into the inhibition of serine proteases by monocyclic lactams.
Wilmouth RC; Kassamally S; Westwood NJ; Sheppard RJ; Claridge TD; Aplin RT; Wright PA; Pritchard GJ; Schofield CJ
Biochemistry; 1999 Jun; 38(25):7989-98. PubMed ID: 10387042
[TBL] [Abstract][Full Text] [Related]
18. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
19. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
[TBL] [Abstract][Full Text] [Related]
20. Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor.
Biroc SL; Gay S; Hummel K; Magill C; Palmer JT; Spencer DR; Sa S; Klaus JL; Michel BA; Rasnick D; Gay RE
Arthritis Rheum; 2001 Mar; 44(3):703-11. PubMed ID: 11263786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
